Abstract: The invention relates generally to the field of compositions including one or more conjugates of di-sugar and a nonsteroidal anti-inflammatory drug (NSAID), and use of same in methods for treating a disease or a disorder in a subject in need thereof.

Abstract: A sterile closed system (20, 120) is provided that includes an airtight enclosure (40), an infusion-bag receptacle (44), medication-preparation tubing (48), one or more medication-preparation-tubing valves (50, 250), and an infusion-bag seal (46), which is configured to make an airtight seal with respective external surfaces of a medication port (36) and an IV tubing port (34) of an infusion bag (32). A medication-vial port (33) is configured to be sealingly coupled to a medication vial (30).

Abstract: A closed-system grinding syringe (10, 110) is provided for liquefying and delivering a solid dosage form (20), including a barrel (22), a fluid port (30) disposed on a bottom wall (28) of the barrel (22), and a plunger (32). A head (36) of the plunger (32) is insertable into and moveable within the barrel (22) such that (a) a portion of the barrel (22) defines a closed-system syringe chamber (46) between the bottom barrel wall (28) and a lower surface (64) of the plunger head (36), and (b) a plunger-head annular seal (42) forms a fluid-tight seal between an outer surface (44) of the plunger head (36) and a cylindrical inner surface (26) of the barrel (22).

Abstract: A compound having the structure: ##STR1## wherein R.sub.1, R.sub.2, and R.sub.3 are independently the same or different and are hydrogen, a C.sub.1 -C.sub.6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3. Also provided are a compound containing a 2-valproenoic moiety, pharmaceutical compositions comprising these compounds, and methods of using them for the effective treatment of epilepsy and other neurological disorders.